Issa Layali - Department of Biochemistry and Biophysics, Faculty of Advanced Sciences and technology, TehranMedical Sciences Branch, Islamic Azad University, Tehran, Iran
Ali Vasheghani Farahani - Department of Cellular and Molecular Biology, Faculty of Advanced Sciences and technology, Tehran MedicalSciences Branch, Islamic Azad University, Tehran, Iran
Pardis Hemmati - Department of Cellular and Molecular Biology, Faculty of Advanced Sciences and technology, Tehran MedicalSciences Branch, Islamic Azad University, Tehran, Iran
Avin Ezzati - Department of Cellular and Molecular Biology, Faculty of Advanced Sciences and technology, Tehran MedicalSciences Branch, Islamic Azad University, Tehran, Iran
Dariush Hossein Panahi - Department of Cellular and Molecular Biology, Faculty of Advanced Sciences and technology, Tehran MedicalSciences Branch, Islamic Azad University, Tehran, Iran
Mobina keshavarzmotamed - Department of Cellular and Molecular Biology, Faculty of Advanced Sciences and technology, Tehran MedicalSciences Branch, Islamic Azad University, Tehran, Iran

CRISPR-associated proteins and Regularly Interspaced Short Palindromic Repeats are referred to as CRISPR-Cas۹.The immune system of bacteria and archaea is adaptive, or acquired. Therefore, creating the greatest Cas۹endonuclease and single controlled RNA proteins and applying the technique in clinical practice will help treatdiseases of many origins, including lung malignancies. An overview of CRISPR-Cas۹ technology, as well aspresent and future uses and viewpoints for the technique, will be covered in this lecture. Additionally, themechanism of action of the technique in lung cancer therapy will be discussed. There are two ways that lungcancer can be treated using this technique. The first strategy entails producing Cas۹ and single guided RNA,which are subsequently delivered to cancer cells via appropriate techniques.By specifically targeting the lung's mutant epidermal growth factor receptor and finding a complementarymatch, single directed RNA can inhibit the growth of cancer by cleaving the receptor with the help of the Cas۹protein. Controlling the expression of ligand-receptors on immunological lymphocytic cells is the secondtechnique. For instance, the CRISPR-Cas۹ system can limit the progression of cancer by preventing lymphocytesfrom expressing cancer receptors, which in turn reduces the amount of contact between the tumor cell and itsligand-receptor.

CRISPR, CAS۹, Cancer, Lung cancer